Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript

Core Points - Tenaya is presenting initial data from Cohort 1 of the RIDGE-1 Phase Ib/II clinical trial for TN-401 gene therapy aimed at treating PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC) [1][2] Group 1 - The presentation is led by Michelle Corral, Vice President of Corporate Communications and Investor Relations at Tenaya [1] - Key executives participating in the call include Faraz Ali (CEO), Dr. Kathy Ivey (SVP of Research), and Dr. Whit Tingley (Chief Medical Officer) [2] - A PDF of the presentation slides is available on Tenaya's website in the Investor Relations section [2] Group 2 - The information shared during the call includes forward-looking statements reflecting the company's perspective as of December 11, 2025 [3] - Investors are cautioned against placing undue reliance on the forward-looking statements due to inherent assumptions [3] - The company will not be taking questions during this call due to the launch [4]